This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
A recent study shows that adding docetaxel (Docefrez, Taxotere) chemotherapy to the standard treatment of hormone therapy and radiation therapy helps men with high-risk, localized prostate cancer live longer.
A large, ongoing study showed that men with advanced prostate cancer who received docetaxel (Docefrez, Taxotere) in addition to standard prostate cancer treatment lived longer than those who received only standard hormone therapy. The study also showed that including zoledronic acid (Zometa) along with docetaxel and standard hormone therapy did not offer additional benefits.
A new study that analyzed data from more than 87,500 men with prostate cancer shows that the number diagnosed with higher-risk disease increased between 2011 and 2013. According to these results, the number of men diagnosed with either intermediate- or high-risk disease has increased by nearly 6% since 2011. These findings are interesting because in 2011 the U.S. Preventive Services Task Force (USPSTF) recommended that PSA testing not be used for prostate cancer screening, regardless of a man’s age.
For many types of cancer, doctors are able to run laboratory tests to identify specific genes, proteins, and other factors unique to the tumor that help determine the best treatment option for each patient. However, there are currently no tests to help doctors select the best treatment option for men with metastatic castration-resistant prostate cancer (mCRPC).
A new study that analyzed data from 945 men with prostate cancer raises questions about recommending active surveillance to men with intermediate-risk disease.
New findings from a large group of patients from the national Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial show that men who have a specific form of baldness – at both the front and crown of the head – at the age of 45 have a 40% increased risk of developing aggressive prostate cancer (usually indicates a faster growing tumor resulting in poorer prognosis, relative to “non-aggressive” prostate cancer) later in life, compared to men with no baldness at that age. However, the researchers did not find a link between any type of baldness and risk of non-aggressive prostate cancer.
Results from a new study led by the National Cancer Institute suggest that adding chemotherapy with the drug docetaxel (Docefrez, Taxotere) to standard hormone therapy lengthens the lives of men newly diagnosed with metastatic hormone-sensitive prostate cancer.
According to a large study, men who have rising prostate-specific antigen (PSA) levels after surgery or radiation therapy may be able to safely hold off on receiving hormone therapy until they experience symptoms or other signs that the cancer has returned.
Results from a new study show that the medication enzalutamide (Xtandi) lengthens the lives of men with metastatic castration-resistant prostate cancer by almost a third. Metastatic castration-resistant prostate cancer (mCRPC) is cancer that has spread to parts of the body other than the prostate and continues to grow and spread without needing the male sex hormone testosterone. Enzalutamide is a type of hormone therapy called an androgen-receptor blocker or an anti-androgen. For men with prostate cancer, hormone therapy is used to block or lower the levels of hormones called androgens that can be involved in prostate cancer growth.
Updated results from a clinical trial conducted in Norway and Sweden show that adding radiation therapy to ongoing oral anti-androgen therapy, a type of hormone therapy, more than halved the rate of deaths from locally advanced prostate cancer, compared to ongoing oral anti-androgen therapy given without radiation therapy. For men with prostate cancer, hormone therapy is used to block or lower the levels of hormones called androgens that can be involved in prostate cancer growth. Locally advanced prostate cancer is when the disease has grown through the capsule, the tissue that covers most of the prostate. When this study first began, surgery was not a standard treatment for this type of prostate cancer, and surgery is still not often used because it can be difficult to remove all of the cancer. Radiation therapy (the use of x-rays to kill cancer cells) is often a good option because it can be directed at tissue beyond the prostate to kill cells outside the capsule.